Last reviewed 2026-04-20 · How we verify

Apetinil (ETILAMFETAMINE)

Phase 2 active Small molecule

Apetinil (generic name: ETILAMFETAMINE) is a etilamfetamine drug. It is currently in Phase 2 development.

Apetinil works by binding to the Sigma non-opioid intracellular receptor 1, which is involved in various physiological processes.

Apetinil (Etilamfetamine) is a small molecule drug that targets the Sigma non-opioid intracellular receptor 1. It is classified as an etilamfetamine, but its commercial status and approved indications are unknown. The mechanism of action and pharmacokinetic properties of Apetinil are also not well-documented. Further research is needed to fully understand the potential benefits and risks of this medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETILAMFETAMINE
Drug class	etilamfetamine
Target	Sigma non-opioid intracellular receptor 1
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2
Annual revenue	172

Mechanism of action

Think of it like a key fitting into a lock. Apetinil is the key that binds to the Sigma receptor, which helps regulate how our cells respond to certain signals. This can affect things like pain perception, mood, and other bodily functions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
SEC EDGAR	Revenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Apetinil CI brief — competitive landscape report
Apetinil updates RSS · CI watch RSS

Frequently asked questions about Apetinil

What is Apetinil?

Apetinil (ETILAMFETAMINE) is a etilamfetamine drug.

How does Apetinil work?

Apetinil works by binding to the Sigma non-opioid intracellular receptor 1, which is involved in various physiological processes.

What is the generic name of Apetinil?

ETILAMFETAMINE is the generic (nonproprietary) name of Apetinil.

What drug class is Apetinil in?

Apetinil belongs to the etilamfetamine class. See all etilamfetamine drugs at /class/etilamfetamine.

What development phase is Apetinil in?

Apetinil is in Phase 2.

What is Apetinil's annual revenue?

Apetinil generated approximately $0.0B in annual revenue.

What does Apetinil target?

Apetinil targets Sigma non-opioid intracellular receptor 1 and is a etilamfetamine.

Drug class: All etilamfetamine drugs
Target: All drugs targeting Sigma non-opioid intracellular receptor 1
Therapeutic area: All drugs in Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing